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Abstract
Background: Nivolumab is an anti-programmed cell death (anti-PD-1) monoclonal antibody that is approved by
Food and Drug Administration for treatment of metastatic non-small cell lung cancer, metastatic melanoma,
relapsed Hodgkin lymphoma and advanced renal cell cancer. We report a rare case of myxedema crisis induced by
nivolumab in a patient with metastatic squamous cell carcinoma of lung.
Case presentation: Fifty three-year old woman with metastatic squamous cell carcinoma currently on treatment
with nivolumab presented with diffuse facial and tongue swelling, slurred speech, depressed mentation, fatigue
and weakness. Initial evaluation revealed severe hypothyroidism with thyroid stimulating hormone of 237 micro
Unit/mL (Normal Reference range: 0.27–4.20 micro unit/mL) and undetectable free T4. Patient was diagnosed with
nivolumab induced myxedema crisis. She was treated successfully with levothyroxine with complete resolution of
her symptoms. Nivolumab was safely restarted once the symptoms of myxedema resolved.
Conclusion: Nivolumab can cause immune-mediated endocrinopathies including thyroiditis, hypophysitis, adrenal
insufficiency and type 1 diabetes mellitus. High index of suspicion and periodic measurement of thyroid function
tests are recommended in patients receiving nivolumab therapy. Our case also suggests that once the myxedema
crisis is treated and symptoms are resolved, nivolumab can be safely re-challenged.
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Background
Cancer treatment has rapidly advanced over the recent
years with exodus of newly approved therapies for various
malignancies. Immunomodulatory agents such as nivolu-
mab have a unique mechanism of action, dramatically dif-
ferent from that of traditional chemotherapy. As a result,
toxic effects are also unique and predominantly immune
mediated. Nivolumab is one example of immunotherapy
drugs, which is approved by Food and Drug Administra-
tion for treatment of metastatic non-small cell lung can-
cer, metastatic melanoma, relapsed Hodgkin’s lymphoma,
metastatic head and neck cancer and advanced renal cell
cancer. Although a number of immune mediated adverse
effects of nivolumab are reported but myxedema is a very
rare adverse effect [1]. Herein, we present a rare case of
nivolumab-mediated myxedema in a patient with non-
small cell lung cancer (NSCLC).
Case presentation
A 53-year-old woman was diagnosed with metastatic
squamous cell carcinoma of lung with involvement of the
liver and mediastinal lymph nodes. She has a history of
hypertension, chronic kidney disease due to prior cisplatin
use and uterine fibroids but no history of thyroid disease
or any other autoimmune disorders. She was receiving
second-line therapy using nivolumab, to which she
achieved excellent response and complete resolution of
liver disease and significant response in the lung and
mediastinal lesions. Programmed death-ligands 1 (PD-L1)
were expressed on 81–90% of malignant cells. She was
doing well until she presented to the emergency depart-
ment with slurred speech, progressive diffuse facial, peri-
orbital swelling and tongue swelling over the last few
weeks. She also complained of generalized weakness, fa-
tigue, forgetfulness, constipation, dyspnea, slow voice, cold
intolerance and dry skin. Physical examination revealed
slightly overweight woman with cushinoid appearance,
depressed mentation, poor memory and delayed relax-
ation phase of deep tendon reflexes. Facial examination
revealed diffuse facial, periorbital and neck swelling. She
* Correspondence: uqba.md@gmail.com
Department of Hematology/Oncology, St. John Hospital and Medical Center,
19229 Mack Ave Suite 23 Grosse Pointe Woods, Detroit 48236, Michigan,
USA
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Khan et al. Journal for ImmunoTherapy of Cancer  (2017) 5:13 
DOI 10.1186/s40425-017-0213-x
has no thyromegaly or lymphadenopathy. The rest of the
examination was unremarkable.
Laboratory findings showed hemoglobin of 87 gm/L,
mean corpuscular volume of 94 fL, white blood cell count
of 4.6 × 109/L, platelets of 238 × 109/L, creatinine of
209.5 μmol/L, sodium of 136 mmol/L, potassium of
4.4 mmol/L and calcium of 2.5 mmol/L. Thyroid function
tests revealed thyroid-stimulating hormone of 237 micro
Unit/mL and free T4 1 pmol/L. Cortisol level was
303 nmol/L. Creatine kinase was elevated at 23.80 μkat/L
suggestive of myopathy due to severe hypothyroidism.
Computed tomography of the brain revealed no evidence
of intracranial metastasis.
These clinical and laboratory findings were consistent
with myxedema crisis. Therefore, she was hospitalized and
immediately initiated on 100 μg of intravenous (IV)
levothyroxine for 3 days. This was followed by 137 μg of
oral levothyroxine daily. In addition, she was started on IV
hydrocortisone which was subsequently discontinued
once adrenal insufficiency was ruled out. She expressed
dramatic recovery of her symptoms and laboratory stud-
ies. Nivolumab was suspected to be the culprit of myx-
edema in this patient and was held until symptoms
improved. She was subsequently restarted on nivolumab
without recurrent symptoms. On continued follow up, she
was given another 10 cycles of nivolumab over 5 months
period without any signs or symptoms of myxedema.
Discussion and conclusions
Cancer treatment has revolutionized in recent years. De-
velopment of new therapies especially immunotherapy has
greatly impacted the outcome of malignant disorders.
However, the toxic effects associated with these agents are
dramatically different from those encountered with
chemotherapy.
There are various immune checkpoints pathways exist
which limit the immune response of the body to reduce
autoimmunity. One such pathway is programmed cell
death pathway (PD-1), which acts as a checkpoint to reduce
T-cell mediated immune responses [2, 3]. PDL-1, which are
present on tumor, attach with the PD1 receptors on T-
lymphocyte and induce signals causing reversible inhibition
of T cell activation and proliferation [2]. By blocking this
interaction of PDL-1 with PD-1, immune response can be
mounted against malignant cells.
Nivolumab is an anti-programmed cell death (anti-PD-
1) monoclonal antibody. The Food and Drug Administra-
tion (FDA) approved this agent for treatment of metastatic
non-small cell carcinoma, metastatic melanoma, relapsed
Hodgkin’s lymphoma, metastatic head and neck cancer
and advanced renal cell carcinoma [4]. Nivolumab is a
well-tolerated agent with the most common side effects
being fatigue, musculoskeletal pain, decreased appetite,
cough, and constipation. Nivolumab is also associated
with several immune-mediated toxic effects such as colitis,
pneumonitis, hepatitis, nephritis, skin-rash and endocrine
glands dysfunction. Immune-mediated endocrinopathies
include thyroiditis, hypophysitis, adrenal insufficiency and
type 1 diabetes mellitus.
Thyroid dysfunction is seen infrequently in patients
receiving nivolumab. Both hyperthyroidism and
hypothyroidism can occur in patients receiving nivo-
lumab. In clinical trials, grade 1 and 2 hyperthyroid-
ism occurred in 1.4–4.4% of patients receiving
nivolumab [5–7]. Grade 3 hyperthyroidism is reported in
one patient with metastatic melanoma receiving nivolu-
mab [8–10]. The median time to its occurrence was about
2–3 months [11]. Grade 1 and 2 hypothyroidism is esti-
mated to occur in 7–9% of patients receiving nivolumab
[5–7]. Grade 3 hypothyroidism was reported in 3 patients,
one with metastatic melanoma and two with renal cell
carcinoma [11, 12]. The median time to development of
hypothyroidism was 2.9 months. It is recommended to
check TSH and free T4 before each treatment.
Management of nivolumab-induced hypothyroidism
depends on severity of the disease. If hypothyroidism is
mild, simple replacement of levothyroxine is sufficient. If
hypothyroidism is moderate or severe as in our case, man-
agement often requires multidisciplinary approach to
avoid life-threatening cardiac complications associated
with levothyroxine replacement. It is recommended to
hold nivolumab in patients with severe hypothyroidism
but it can be reinstituted once the patient is stabilized, as
in our patient.
Checkpoint inhibitors especially nivolumab have revolu-
tionized the treatment of various hematological and solid
malignancies. It is not only important for oncologists but
as well as for general practitioners to be familiarize with
unusual adverse effects of these drugs. Immune mediated
thyroid dysfunction remains an important adverse effect
of checkpoint inhibitors. It has become our routine prac-
tice to check baseline thyroid function tests and monitor
them periodically during the nivolumab treatment. It is
recommended to check TSH and free T4 before every
cycle of nivolumab.
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